Publication details
Nové možnosti léčby pokročilého nebo recidivujícího endometriálního karcinomu - dostarlimab
| Title in English | New treatment options for advanced or recurrent endometrial cancer - dostarlimab |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Profi Medicína |
| MU Faculty or unit | |
| Citation | |
| Web | https://profimedicina.cz/nove-moznosti-lecby-pokrocileho-nebo-recidivujiciho-endometrialniho-karcinomu-dostarlimab/ |
| Keywords | endometrial carcinoma; treatment; dostarlimab |
| Description | The new drugs in endometrial cancer are related to conventional chemotherapy and belong to the armamentarium of advanced, metastatic and recurrent stages of the disease, which still have a poor prognosis. New systemic therapies include monoclonal antibodies (lenvatinib, trastuzumab), checkpoint inhibitors (dostarlimab, pembrolizumab) and targeted agents (especially from the kinase inhibitor group). In clinical practice, the efficacy of immuno-oncotherapeutics in monotherapy has been confirmed to be low in gynaecological malignancies; they are usually combined with conventional chemotherapy or targeted drugs. Significant synergistic efficacy of the combination of dostarlimab + carboplatin with paclitaxel in a cohort of patients with hypermutated carcinoma has been described. The significance of the success of these therapeutics is also demonstrated by a recent change in the recommended practice guidelines of the Czech Oncological Society. |